Limits...
Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients.

Matas E, Bau L, Martínez-Iniesta M, Romero-Pinel L, Mañé MA, Cobo-Calvo Á, Martínez-Yélamos S - PLoS ONE (2014)

Bottom Line: There is little available data on clinical utility of baseline MxA mRNA status.Baseline MxA mRNA expression was significantly lower in the group of patients who met the definition of responders (1.07 vs 1.95, Student t test, p<0.0001).A threshold of 1.096 was established using Receiver Operating Characteristic analysis to differentiate between responders and non-responders (sensitivity 73.9%, specificity 69.0%).

View Article: PubMed Central - PubMed

Affiliation: Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

ABSTRACT

Background: Myxovirus resistance protein A (MxA) is a molecule induced after interferon-beta injection, mostly used to evaluate its bioactivity. There is little available data on clinical utility of baseline MxA mRNA status. The objective of the study is to investigate whether baseline MxA mRNA expression can predict relapse and disease progression in multiple sclerosis patients treated with interferon-beta.

Methods: Baseline blood samples were obtained before the first interferon-beta dose was administered to evaluate MxA mRNA expression using real-time polymerase chain reaction (PCR). Demographic and clinical variables were prospectively recorded to define treatment responder and non responder groups.

Results: 104 patients were included in the study. Baseline MxA mRNA expression was significantly lower in the group of patients who met the definition of responders (1.07 vs 1.95, Student t test, p<0.0001). A threshold of 1.096 was established using Receiver Operating Characteristic analysis to differentiate between responders and non-responders (sensitivity 73.9%, specificity 69.0%). Survival analysis using this threshold showed that time to next relapse (p<0.0001) and to EDSS progression (p = 0.01) were significantly higher in patients with lower MxA titers.

Conclusion: The results suggest that baseline MxA mRNA levels may be useful for predicting whether multiple sclerosis patients will respond or not to interferon-beta treatment.

Show MeSH

Related in: MedlinePlus

Survival curve for the time to EDSS progression using the 1.096 threshold.Patients belonging to the low-MxA group (MxA <1.096) showed a significantly longer time to increase by one point on the EDSS scale (p = 0.01).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4232440&req=5

pone-0112758-g002: Survival curve for the time to EDSS progression using the 1.096 threshold.Patients belonging to the low-MxA group (MxA <1.096) showed a significantly longer time to increase by one point on the EDSS scale (p = 0.01).

Mentions: Survival analysis for relapses (Fig. 1) and EDSS progression (Fig. 2) was performed using the 1.096 threshold. In the low MxA group, the time to the next relapse and to increase one point on the EDSS scale confirmed at 6 months was significantly longer compared with the high MxA group (25% of patients experienced the next relapse (percentile 75) in 2.14 years in the low-MxA group vs 0.40 years in the high-MxA group, log-rank p<0.0001)(25% of patients experienced EDSS progression (percentile 75) in undefined time in low-MxA group vs 2.09 years in the high-MxA group, log-rank p = 0.01).


Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients.

Matas E, Bau L, Martínez-Iniesta M, Romero-Pinel L, Mañé MA, Cobo-Calvo Á, Martínez-Yélamos S - PLoS ONE (2014)

Survival curve for the time to EDSS progression using the 1.096 threshold.Patients belonging to the low-MxA group (MxA <1.096) showed a significantly longer time to increase by one point on the EDSS scale (p = 0.01).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4232440&req=5

pone-0112758-g002: Survival curve for the time to EDSS progression using the 1.096 threshold.Patients belonging to the low-MxA group (MxA <1.096) showed a significantly longer time to increase by one point on the EDSS scale (p = 0.01).
Mentions: Survival analysis for relapses (Fig. 1) and EDSS progression (Fig. 2) was performed using the 1.096 threshold. In the low MxA group, the time to the next relapse and to increase one point on the EDSS scale confirmed at 6 months was significantly longer compared with the high MxA group (25% of patients experienced the next relapse (percentile 75) in 2.14 years in the low-MxA group vs 0.40 years in the high-MxA group, log-rank p<0.0001)(25% of patients experienced EDSS progression (percentile 75) in undefined time in low-MxA group vs 2.09 years in the high-MxA group, log-rank p = 0.01).

Bottom Line: There is little available data on clinical utility of baseline MxA mRNA status.Baseline MxA mRNA expression was significantly lower in the group of patients who met the definition of responders (1.07 vs 1.95, Student t test, p<0.0001).A threshold of 1.096 was established using Receiver Operating Characteristic analysis to differentiate between responders and non-responders (sensitivity 73.9%, specificity 69.0%).

View Article: PubMed Central - PubMed

Affiliation: Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

ABSTRACT

Background: Myxovirus resistance protein A (MxA) is a molecule induced after interferon-beta injection, mostly used to evaluate its bioactivity. There is little available data on clinical utility of baseline MxA mRNA status. The objective of the study is to investigate whether baseline MxA mRNA expression can predict relapse and disease progression in multiple sclerosis patients treated with interferon-beta.

Methods: Baseline blood samples were obtained before the first interferon-beta dose was administered to evaluate MxA mRNA expression using real-time polymerase chain reaction (PCR). Demographic and clinical variables were prospectively recorded to define treatment responder and non responder groups.

Results: 104 patients were included in the study. Baseline MxA mRNA expression was significantly lower in the group of patients who met the definition of responders (1.07 vs 1.95, Student t test, p<0.0001). A threshold of 1.096 was established using Receiver Operating Characteristic analysis to differentiate between responders and non-responders (sensitivity 73.9%, specificity 69.0%). Survival analysis using this threshold showed that time to next relapse (p<0.0001) and to EDSS progression (p = 0.01) were significantly higher in patients with lower MxA titers.

Conclusion: The results suggest that baseline MxA mRNA levels may be useful for predicting whether multiple sclerosis patients will respond or not to interferon-beta treatment.

Show MeSH
Related in: MedlinePlus